Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 5/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241153 | 0.83 | CA1 (0.47) | RECQLLOXLOXL3LOXL2PTGS2 | |
| SCHEMBL6883165 | 0.83 | PTGS2 (0.46) | ALDH1A1RECQLLOXLOXL3LOXL2 | |
| SCHEMBL19928748 | 0.83 | ALDH1A1 (0.43) | TDP1ALDH1A1HSD17B10LOXL2SMARCA2 | |
| SCHEMBL30700822 | 0.83 | PTGS2 (0.46) | ALDH1A1RECQLLOXLOXL3LOXL2 | |
| Hydrochloric Acid SCHEMBL28177603 | 0.81 | RECQL (0.42) | TDP1ALDH1A1HSD17B10RECQLLOX | |
| SCHEMBL29131027 | 0.79 | PSIP1 (0.42) | ALDH1A1RECQLLOXLOXL3LOXL2 | |
| SCHEMBL15390838 | 0.79 | PTGS2 (0.38) | ALDH1A1RECQLLOXLOXL3LOXL2 | |
| SCHEMBL3449694 | 0.78 | UHRF1 (0.46) | TDP1ALDH1A1HSD17B10SMARCA2SMARCA4 | |
| SCHEMBL30410070 | 0.78 | UHRF1 (0.46) | TDP1ALDH1A1HSD17B10SMARCA2SMARCA4 | |
| SCHEMBL15392663 | 0.78 | CA12 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204007-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1 INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2022-06-28 | — | — | US | disclosed |
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2022-06-28 | — | — | US | disclosed |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-08-27 | — | — | US | disclosed |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-08-27 | — | — | US | disclosed |
| EP-3649112-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2020-05-13 | — | — | EP | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-8598154-B2 | Pyridyl-amine fused azadecalin modulators | CORCEPT THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2609097-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | Corcept Therapeutics, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120220565-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012027702-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | TDP1 888/4885ALDH1A1 1215/4885HSD17B10 2040/4885 |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | CFTR, KCNJ11, KCNJ1 | TDP1 1350/4885ALDH1A1 507/4885HSD17B10 2878/4885 |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | TDP1 888/4885ALDH1A1 1215/4885HSD17B10 2040/4885 |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | TDP1 1350/4885ALDH1A1 507/4885HSD17B10 2878/4885 |
| US-20120220565-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | NR3C1, NR3C2, NR5A2 | TDP1 2556/4885ALDH1A1 4358/4885HSD17B10 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.